Symprove probiotic for ongoing gut symptoms in coeliac disease
Official title: A Proof-of-Concept Study to Assess the Efficacy of Symprove Probiotics in Managing Persistent Gastrointestinal Symptoms in Adult Coeliac Disease Patients in Histological Remission
Run by Sheffield Teaching Hospitals NHS Foundation Trust · NCT07360106 · Data updated 2026-11-12
This will try the Symprove probiotic drink to see if it reduces ongoing gut symptoms in adults with coeliac disease who are already following a strict gluten‑free diet.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Sheffield Teaching Hospitals NHS Foundation Trust Academic / other |
| Locations | 1 site (Sheffield, South Yorkshire) |
| Status | Recruiting |
| Started | January 29, 2026 |
| Main results expected | September 2026 |
| Study ends | December 2026 |
| Registry record updated | March 17, 2026 |
| Trial ID | NCT07360106 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 with biopsy‑confirmed coeliac disease in histological remission (Marsh 0 or I), on a strict gluten‑free diet for at least six months, and with persistent gastrointestinal symptoms for at least six months.
✕Probably not a fit
People who are pregnant or breastfeeding, recently used antibiotics or probiotics, have other major gastrointestinal diseases, are not adherent to a gluten‑free diet, or are outside the 18–65 age range are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial gives the Symprove probiotic drink to adults with biopsy‑confirmed coeliac disease who are in histological remission but continue to have gastrointestinal symptoms. Eligible participants are aged 18–65, have a normal or near‑normal duodenal biopsy (Marsh 0 or I) within the past 12 months, and have followed a strict gluten‑free diet for at least six months. Participants will take the probiotic daily and symptom measures will be recorded before and after the treatment period to see if symptoms improve. Common exclusions include recent antibiotic or probiotic use, pregnancy or lactation, and other significant gastrointestinal disorders, and the trial is run at Sheffield Teaching Hospitals.
Why it matters
Potential benefit: If successful, Symprove could reduce persistent gut symptoms and improve day‑to‑day quality of life for people with coeliac disease who remain symptomatic despite a gluten‑free diet.
How similar studies have gone: Probiotic treatments have produced mixed results in small trials for IBS‑type symptoms and have not been definitively proven for persistent symptoms in coeliac disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults aged 18-65 years with biopsy-confirmed coeliac disease (CD) Normal duodenal biopsy (Marsh 0 or Marsh I) within the last 12 months, confirming histological remission Adherence to a strict gluten-free diet (GFD) for at least 6 months Persistent gastrointestinal (GI) symptoms for at least 6 months despite adherence to GFD and histological remission Ability to provide written informed consent Exclusion Criteria: Active gluten ingestion or non-adherence to a gluten-free diet Use of antibiotics within the past 3 months Use of probiotics within the past 3 months Known comorbidities affecting gastrointestinal function (e.g., Crohn's disease, ulcerative colitis, irritable bowel syndrome with severe diarrhea, or other significant gastrointestinal disorders) Pregnancy or lactation Inability to provide informed consent
Where it's running
-
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorkshire, United Kingdom Recruiting
Study contacts
- Principal investigator: David S Sanders, MBChB, MD — Sheffield Teaching Hospitals NHS Foundation Trust
- Study coordinator: David S Sanders, MBChB, MD
- Email: david.sanders1@nhs.net
- Phone: 0114 271 3412
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Barley and kefir to support gut health in active adults
This study tests whether a daily barley and kefir meal for four weeks can change gut microbiota in physically active adults and whether those changes relate to certain metabolites in blood and urine.
-
Probiotics to Prevent Pneumonia in Critically Ill Kids in the PICU
We’re testing whether giving probiotics to critically ill children on a ventilator helps prevent ventilator-associated pneumonia.
-
Probiotic Y7 cocktail to help with early Parkinson’s symptoms
A 12-week randomized trial will test whether a probiotic Y7 cocktail helps people with early Parkinson’s disease by possibly improving motor, thinking, and everyday symptoms.
-
Comparing probiotic and ethyl lauroyl arginate mouthwashes for lowering cavity‑causing bacteria and plaque in Egyptian schoolchildren
This study will test whether a probiotic mouthwash or an ethyl lauroyl arginate mouthwash better lowers Streptococcus mutans, reduces dental plaque, and affects salivary pH in healthy Egyptian children aged 6–12.
-
On-demand dietitian webinar for adults with coeliac disease
This test tries whether a pre-recorded, on-demand webinar led by specialist dietitians can help adults newly diagnosed with coeliac disease learn to follow a gluten-free diet as well as a traditional one-on-one appointment.
-
Using Transcranial Magnetic Stimulation and Probiotics to Treat IBS-D
This study is testing if a combination of brain stimulation and probiotics can help people with diarrhea-predominant IBS feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.